

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: June 20, 2016	
Re.: Press Release.	

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 20, 2016, titled **“Zydus acquires two ANDAs from Teva, strengthens its US portfolio.”** The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited



Upen H. Shah
Company Secretary



Encl.: As above.

Zydus acquires two ANDAs from Teva, strengthens its US portfolio

Ahmedabad, 20 June 2016

Zydus has strengthened its US portfolio with the acquisition of two ANDAs from Teva that are being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs is contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission. The financial details of the transaction are undisclosed.

The company said that these ANDAs have been acquired by its 100% subsidiary, Zydus Worldwide DMCC and the transaction will be financed through the group's internal accruals. The acquired portfolio comprises an ANDA which is already commercialised and one pipeline ANDA which is a transdermal patch. The estimated market size of the two ANDAs put together is nearly US\$ 200 Mio.

Speaking on the development, Mr. Pankaj R. Patel, Chairman and Managing Director of the Zydus Group said that this is an important acquisition which will help Zydus to expand its existing portfolio in the US and strengthen its pipeline of complex generic products. Zydus has made significant investments in the transdermal manufacturing technology and had also acquired a transdermal manufacturing facility in the US, a few years ago. He said, "Zydus is upbeat about the growth potential in the US and will continue to pursue more inorganic opportunities in the US market."

About Zydus Cadila

Headquartered in Ahmedabad, India, Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19000 people worldwide. The group has a strong research pipeline of NCEs, biologics and vaccines and has over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. In 2013, the group was the first to identify and develop Lipaglyn (Saroglitazar) and launch India's first NCE in the market. In 2014, the group launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. As a leading healthcare provider, the group aims to become a global research based pharmaceutical company by 2020.